Biophytis S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BPTS research report →
About the company
Biophytis S. A. operates as a clinical-stage biotechnology firm dedicated to advancing therapeutic solutions aimed at decelerating degenerative processes and enhancing functional outcomes for individuals grappling with age-related illnesses.
- CEO
- Stanislas Veillet
- IPO
- 2021
- Employees
- 22
- HQ
- Paris, FR
Price Chart
- Market Cap
- $2.61M
- P/E
- -0.01
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- -1.23
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 153.48%
- ROIC
- -2242.74%
- Revenue
- $0 · 0.00%
- Net Income
- $-17,026,000 · 29.69%
- EPS
- $-12.55 · 77.61%
- Op Income
- $-14,333,000
- FCF YoY
- 31.55%
- 52W High
- $168.80
- 52W Low
- $8.05
- 50D MA
- $16.44
- 200D MA
- $35.77
- Beta
- 1.05
- Avg Volume
- 9.04K
Get TickerSpark's AI analysis on BPTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BPTS coverage
Recent articles, reports, and earnings notes.
No research on BPTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BPTS report →Similar companies
Peers in the same neighborhood.